Pamela J. Björkman

This paper introduces Duality vaccination, a method that delivers both activating and inhibitory stimuli to shape antibody responses, using nanoparticle-based immunogens.

This study identifies nanobodies targeting conserved SARS-CoV-2 RBD epitopes that neutralize variants and zoonotic sarbecoviruses.

The paper identifies extensive membrane contact sites between the mealybug endosymbiont Tremblaya and host mitochondria, suggesting these interactions provide essential membrane and metabolic components.

This paper develops mRNA-based vaccines encoding RBD quartets and shows they match or improve antibody breadth, T-cell responses, and epitope targeting compared to protein-based vaccines.

This paper develops a gp120-specific CD4 variant (gCD4) that improves thermostability, reduces off-target class II MHC binding, and enhances HIV-1 neutralization compared to existing CD4-Ig biologics.

This study demonstrates a method to generate antigen-presenting vesicles displaying pMHCI using engineered constructs, which selectively stimulate T cells for potential cell-free immunotherapy.

This paper develops a recombinant single-cycle influenza viral vector vaccine against SARS-CoV-2 and SARS-like betacoronaviruses, showing robust immune responses in mice.

This study shows a novel two-step mechanism for inducing broadly neutralizing HIV antibodies in macaques using a modified SHIV, informing vaccine design.

This study evaluates ALD-delivered mosaic-8b RBD-nanoparticles, showing improved cross-reactive antibody responses against mismatched sarbecoviruses compared to conventional immunizations.

This study shows that PPARγ downregulation in colonic CD8+ T cells of people with HIV on ART leads to epithelial barrier disruption by promoting lipid uptake and apoptosis.

This paper identifies a potent, broad neutralizing antibody targeting a glycan-independent V3 epitope on HIV-1 Env, showing enhanced neutralization potency and resistance to escape mutations.

The paper identifies a new broadly neutralizing antibody, 04_A06, with high potency and breadth against HIV-1 strains, showing potential for prevention and therapy.

This study evaluates bivalent S-EABR mRNA-LNP boosters in pre-vaccinated mice, showing enhanced neutralizing responses and polyclass RBD antibody diversity against SARS-CoV-2 variants.

This paper designs and tests an HIV-1 vaccine candidate that targets three bNAb epitopes, showing it elicits combined immune responses in animal models.

The paper identifies ACE2 as a receptor for HKU5 coronaviruses from Pipistrellus abramus bats and investigates receptor tropism across merbecovirus clades.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper identifies minimal somatic hypermutations required for CD4bs bNAb neutralization breadth and uses structural data to guide HIV-1 vaccine immunogen design.

The paper identifies a mutation in the SARS-CoV-2 nucleocapsid protein that enhances viral infection by promoting dimer formation and altering virion structure.

The paper designs mosaic nanoparticles with SARS-like betacoronavirus RBDs to enhance cross-reactive immune responses in mice, finding that mosaic-7COM elicits stronger responses against zoonotic sarbecoviruses and Omicrons.

This study identifies two bovine-derived monoclonal antibodies with ultra-long CDRH3 domains that broadly neutralize SARS-CoV-2 and sarbecoviruses.

This study shows that sequential immunization of macaques with engineered and native-like HIV-1 Env trimers elicits antibodies that neutralize by targeting non-closed Env conformations.

The paper uses electron tomography to visualize HIV-1 virions trapped by fusion inhibitors in infected tissues, revealing pre-hairpin intermediates linked to host cells.

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

The paper detects and characterizes the SARS-CoV-2 lineage B.1.526 in New York, showing its rapid growth and potential impact on neutralization.

The paper classifies neutralizing antibodies against SARS-CoV-2 spike RBD based on structure, identifying binding modes and implications for vaccine and therapeutic strategies.

The paper analyzes HIV-1 broadly neutralizing antibodies to classify epitopes and identify potential vaccine candidates based on structural and immunological features.